Anti-fibrotic effects of branched-chain amino acids on hepatic stellate cells = Anti-fibrotic effects of branched-chain amino acids on hepatic stellate cells

다국어 초록 (Multilingual Abstract)

Background/Aims: Patients with liver cirrhosis (LC) have low levels of branched-chain amino acids (BCAAs). There is accumulating evidence that BCAAs have anti-fibrotic effects in cirrhosis. This study is aimed to evaluate the effect of BCAAs on the function and phenotype of activated hepatic stellate cells (HSCs).
Methods: LX-2, an immortalized human stellate cell line, was used in in vitro experiments. LX-2 cells were exposed to transforming growth factor β1 (TGF-β1) and BCAAs or to valine, leucine, and isoleucine, which are components of BCAAs. Activation of the TGF-β signaling pathway in LX-2 cells was observed using real-time quantitative polymerase chain reaction and Western blotting.
Results: The increased expression of snail family transcriptional repressor 1 (SNAI1) was observed in LX-2 cells activated by TGF-β1. After BCAA treatment, its expression was significantly decreased at the mRNA level. The increased expression of Col1α1 and TIMP2 at the mRNA level and alpha smooth muscle actin at the protein level in activated LX-2 cells decreased after BCAA treatment. Among the BCAA components, leucine and valine significantly abrogated TGF-β-induced activation of LX-2 cells. BCAA treatment led to the decreased phosphorylation of Smad2 and p38 proteins, which are markers for Smad and Smad-independent p38 mitogen-activated protein kinase signaling pathways, respectively.
Conclusions: BCAA treatment can improve hepatic fibrosis by directly affecting the activated state of hepatic stellate cells through inhibition of the TGF-β signaling pathway. Among BCAA components, leucine and valine mainly abrogated TGF-β- induced activation of HSCs. Our results suggest that BCAA may be used to attenuate the progression of liver fibrosis.

참고문헌 (Reference)

1 Rockey DC, "Zakim and Boyer’s Hepatology" Saunders/Elsevier 64-85, 2012

2 Holecek M, "Three targets of branched-chain amino acid supplementation in the treatment of liver disease" 26 : 482-490, 2010

3 Wong MCS, "The growing burden of liver cirrhosis : implications for preventive measures" 12 : 201-203, 2018

4 Dewidar B, "TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019" 8 : 1419-, 2019

5 Xu J, "TGF-beta-induced epithelial to mesenchymal transition" 19 : 156-172, 2009

6 Scarpa M, "Snail1 transcription factor is a critical mediator of hepatic stellate cell activation following hepatic injury" 300 : G316-G326, 2011

7 Lynch CJ, "Role of leucine in the regulation of mTOR by amino acids : revelations from structure-activity studies" 131 : 861-, 2001

8 Marchesini G, "Nutritional supplementation with branched-chain amino acids in advanced cirrhosis : a double-blind, randomized trial" 124 : 1792-1801, 2003

9 Zhang YE, "Non-smad signaling pathways of the TGF-β family" 9 : a022129-, 2017

10 Zhang YE, "Non-Smad pathways in TGF-beta signaling" 19 : 128-139, 2009

11 Moustakas A, "Non-Smad TGF-beta signals" 118 : 3573-3584, 2005

12 Pereira MG, "Leucine supplementation accelerates connective tissue repair of injured tibialis anterior muscle" 6 : 3981-4001, 2014

13 Gandhi CR, "Hepatic stellate cell activation and pro-fibrogenic signals" 67 : 1104-1105, 2017

14 이천주 ; 김성민 ; 허원희 ; 최정은 ; 김정희 ; 홍성우 ; 이은별 ; 이준호 ; 윤승규, "Elk-3 Contributes to the Progression of Liver Fibrosis by Regulating the Epithelial-Mesenchymal Transition" 거트앤리버 소화기연관학회협의회 11 (11): 102-111, 2017

15 Park JG, "Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease:a Korean nationwide, multicenter, retrospective, observational, cohort study" 96 : e6580-, 2017

16 Park JG, "Effects of branched-chain amino acid(BCAA)supplementation on the progression of advanced liver disease : a Korean nationwide, multicenter, prospective, observational, cohort study" 12 : 1429-, 2020

17 Takegoshi K, "Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model" 8 : 18191-18205, 2017

18 Lynch CJ, "Branched-chain amino acids in metabolic signalling and insulin resistance" 10 : 723-736, 2014

19 Kawaguchi T, "Branched-chain amino acids as pharmacological nutrients in chronic liver disease" 54 : 1063-1070, 2011

20 Cha JH, "Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis" 8 : e77899-, 2013

21 Khedr NF, "Branched chain amino acids supplementation modulates TGF-β1/Smad signaling pathway and interleukins in CCl4-induced liver fibrosis" 31 : 534-545, 2017

22 Zarubin T, "Activation and signaling of the p38 MAP kinase pathway" 15 : 11-18, 2005